Breakthrough vaccine for deadliest skin cancer cuts risk by almost half

A breakthrough vaccine has cut the risk of death or melanoma recurrence by nearly half, an encouraging signal for a treatment seeking federal approval that has improved the fortunes of drugmakers Moderna and Merck and could pave the way for a new wave of cancer treatments.